§ 95.628   MedRadio transmitters in the 413-419 MHz, 426-432 MHz, 438-444 MHz,
and 451-457 MHz and 2360-2400 MHz bands.

   The following provisions apply to MedRadio transmitters operating in the
   413-419 MHz, 426-432 MHz, 438-444 MHz, and 451-457 MHz bands as part of a
   Medical Micropower Network (MMN) and in the 2360-2400 MHz band as part of a
   Medical Body Area Network (MBAN).

   (a) Operating frequencies. A MedRadio station authorized under this part
   must have out-of-band emissions that are attenuated in accordance with
   § 95.635.

   (1)  Only MedRadio stations that are part of an MMN may operate in the
   413-419 MHz, 426-432 MHz, 438-444 MHz, and 451-457 MHz frequency bands. Each
   MedRadio station that is part of an MMN must be capable of operating in each
   of the following frequency bands: 413-419 MHz, 426-432 MHz, 438-444 MHz, and
   451-457  MHz. All MedRadio stations that are part of a single MMN must
   operate in the same frequency band.

   (2) Only MedRadio stations that are part of an MBAN may operate in the
   2360-2400 MHz frequency band.

   (b) Requirements for a Medical Micropower Network. (1) Frequency monitoring.
   MedRadio programmer/control transmitters must incorporate a mechanism for
   monitoring the authorized bandwidth of the frequency band that the MedRadio
   transmitters intend to occupy. The monitoring system antenna shall be the
   antenna used by the programmer/control transmitter for a communications
   session.

   (i)  The  MedRadio  programmer/control transmitter shall be capable of
   monitoring  any occupied frequency band at least once every second and
   monitoring alternate frequency bands within two seconds prior to executing a
   change to an alternate frequency band.

   (ii) The MedRadio programmer/control transmitter shall move to another
   frequency band within one second of detecting a persistent (i.e., lasting
   more than 50 milliseconds in duration) signal level greater than −60 dBm as
   received  by a 0 dBi gain antenna in any 12.5 kHz bandwidth within the
   authorized bandwidth.

   (iii)  The MedRadio programmer/control transmitter shall be capable of
   monitoring  the authorized bandwidth of the occupied frequency band to
   determine whether either direction of the communications link is becoming
   degraded to the extent that communications is likely to be lost for more
   than  45  milliseconds.  Upon making such a determination the MedRadio
   programmer/control transmitter shall move to another frequency band.

   (2)  MedRadio  transmitters. MedRadio transmitters shall incorporate a
   programmable means to implement a system shutdown process in the event of
   communication failure, on command from the MedRadio programmer/control
   transmitter, or when no frequency band is available. The shutdown process
   shall commence within 45 milliseconds after loss of the communication link
   or receipt of the shutdown command from the MedRadio programmer/control
   transmitter.

   (3) MedRadio programmer/control transmitters. MedRadio programmer/control
   transmitters shall have the ability to operate in the presence of other
   primary and secondary users in the 413-419 MHz, 426-432 MHz, 438-444 MHz,
   and 451-457 MHz bands.

   (4) Authorized bandwidth. The 20 dB authorized bandwidth of the emission
   from a MedRadio station operating in the 413-419 MHz, 426-432 MHz, 438-444
   MHz, and 451-457 MHz bands shall not exceed 6 MHz.

   (c)   Requirements   for   Medical  Body  Area  Networks.  A  MedRadio
   programmer/control  transmitter  and  its associated medical body-worn
   transmitters shall not commence operating in, and shall automatically cease
   operating in, the 2360-2390 MHz band if the programmer/control transmitter
   does  not  receive,  in accordance with the protocols specified by the
   manufacturer, a control message permitting such operation. Medical body-worn
   transmitters  shall  cease  operating  in  2360-2390  MHz if they lose
   communication  with  their  associated programmer/control transmitter.
   Additionally, a MedRadio programmer/control transmitter and its associated
   medical body-worn transmitters operating in the 2360-2390 MHz band shall
   comply  with  a  control  message  that  notifies the devices to limit
   transmissions to segments of the 2360-2390 MHz band or to cease operation in
   the band.

   (d) Frequency stability. Each transmitter in the MedRadio service must
   maintain a frequency stability of ±100 ppm of the operating frequency over
   the range:

   (1) 25 °C to 45 °C in the case of medical implant transmitters; and

   (2) 0 °C to 55 °C in the case of MedRadio programmer/control transmitters
   and Medical body-worn transmitters.

   (e) Shared access. The provisions of this section shall not be used to
   extend the range of spectrum occupied over space or time for the purpose of
   denying fair access to spectrum for other MedRadio systems.

   (f) Measurement procedures. (1) MedRadio transmitters shall be tested for
   frequency  stability,  radiated emissions and EIRP limit compliance in
   accordance with paragraphs (f)(2) and (3) of this section.

   (2) Frequency stability testing shall be performed over the temperature
   range set forth in (d) of this section.

   (3) Radiated emissions and EIRP limit measurements may be determined by
   measuring the radiated field from the equipment under test at 3 meters and
   calculating the EIRP. The equivalent radiated field strength at 3 meters for
   1 milliwatt, 25 microwatts, 250 nanowatts, and 100 nanowatts EIRP is 115.1,
   18.2, 1.8, or 1.2 mV/meter, respectively, when measured on an open area test
   site; or 57.55, 9.1, 0.9, or 0.6 mV/meter, respectively, when measured on a
   test site equivalent to free space such as a fully anechoic test chamber.
   Compliance with the maximum transmitter power requirements set forth in
   § 95.639(f) shall be based on measurements using a peak detector function and
   measured over an interval of time when transmission is continuous and at its
   maximum power level. In lieu of using a peak detector function, measurement
   procedures  that have been found to be acceptable to the Commission in
   accordance  with  § 2.947  of  this  chapter may be used to demonstrate
   compliance. For a transmitter intended to be implanted in a human body,
   radiated emissions and EIRP measurements for transmissions by stations
   authorized  under  this  section  may  be  made  in  accordance with a
   Commission-approved human body simulator and test technique. A formula for a
   suitable tissue substitute material is defined in OET Bulletin 65 Supplement
   C (01-01).

   [ 77 FR 55732 , Sept. 11, 2012, as amended at  79 FR 60099 , Oct. 6, 2014]

   return arrow Back to Top